Abstract: Small molecule targeted anti-tumor drugs represented by tyrosine kinase inhibitors(TKIs) have become a new hotspot in the research of cancer therapeutic drugs due to their high selectivity and low toxicity, and more and more studies of population pharmacokinetics (PPK) in TKIs are reported. This article summarize the progress of PPK research on TKIs used in common tumor, listed the PPK model structure parameters and covariates, and summarized whether they need to be adjusted according to relevant influencing factors, in order to provide reference for rationally use of TKIs in clinical and pharmacokinetic- pharmacodynamics(PK-PD) studies.